BioLineRx (BLRX) Interest & Investment Income (2011 - 2026)
BioLineRx (BLRX) posted quarterly Interest & Investment Income of $303000.0 for Q4 2025, down 10.09% year-over-year from $337000.0 in Q4 2024, and down 19.63% quarter-over-quarter from $377000.0 in Q3 2025.
Powered by 
Analysis
BioLineRx (BLRX) Interest & Investment Income (2011 - 2026) Analysis & Trends
BioLineRx's Interest & Investment Income history runs 14 years deep, the most recent figure standing at $303000.0 for Q4 2025.
- In Q4 2025, Interest & Investment Income fell 10.09% year-over-year to $303000.0; the TTM figure through Dec 2025 stood at $1.5 million (down 21.75% YoY), while the FY2025 annual figure was $1.5 million, down 21.75% from the prior year.
- Interest & Investment Income for Q4 2025 stood at $303000.0, down from $377000.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $779000.0 in Q4 2023, with the low at $52000.0 in Q3 2021.
- The 5-year median for Interest & Investment Income is $324500.0 (2023), against an average of $332800.0.
- The sharpest annual moves came in 2021 and 2024: Interest & Investment Income soared 1081.82% in 2021, then sank 56.74% in 2024.
- BioLineRx's Interest & Investment Income stood at $260000.0 in 2021, then jumped by 68.46% to $438000.0 in 2022, then jumped by 77.85% to $779000.0 in 2023, then tumbled by 56.74% to $337000.0 in 2024, then decreased by 10.09% to $303000.0 in 2025.
- Business Quant data shows BLRX's Interest & Investment Income at $303000.0 in Q4 2025, $377000.0 in Q3 2025, and $490000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.80 Bn | 130.95 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.54 Bn | 77.55 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.07 Bn | 52.93 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.01 Bn | 44.01 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.40 Bn | 32.09 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.57 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | 10.98 Mn |
| 10 | BioLineRx | 6.46 Bn | 6.46 Bn | 235,000.00 | 132,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 132,000.00 |
| Mar 31, 2026 | 208,000.00 |
| Dec 31, 2025 | 303,000.00 |
| Sep 30, 2025 | 377,000.00 |
| Jun 30, 2025 | 490,000.00 |
| Mar 31, 2025 | 294,000.00 |
| Dec 31, 2024 | 337,000.00 |
| Sep 30, 2024 | 434,000.00 |
| Jun 30, 2024 | 535,000.00 |
| Mar 31, 2024 | 565,000.00 |
| Dec 31, 2023 | 779,000.00 |
| Sep 30, 2023 | 312,000.00 |
| Jun 30, 2023 | 440,000.00 |
| Mar 31, 2023 | 537,000.00 |
| Dec 31, 2022 | 438,000.00 |
| Sep 30, 2022 | 109,000.00 |
| Jun 30, 2022 | 80,000.00 |
| Mar 31, 2022 | 67,000.00 |
| Dec 31, 2021 | 260,000.00 |
| Sep 30, 2021 | 52,000.00 |